Justin Letendre
Synthetic Biology Scientist Strand Therapeutics Inc.
Seminars
Wednesday 27th May 2026
Maximizing Durable & Tissue-Selective Therapeutic Expression with Replicating RNA to Accelerate Clinical Translation of STX-001 & Advance STX-003 Toward IND
11:30 am
- Demonstrate translational insights from STX-001 to validate tolerability, expression durability and clinical feasibility of replicating RNA as a therapeutic modality
- Unlocking extrahepatic therapeutic opportunities with STX-003 through delivery-agnostic gene circuits that enhance tissue specificity, minimize off-target activity and broaden indication scope
- Enabling more complex and potent therapeutic designs by integrating replicating RNA architecture with programmable gene circuits to achieve controlled, high-impact expression in vivo
